Our proprietary sequence-based AI platforms cover the full spectrum of therapeutic modalities, from small molecules to cell therapies.
Protein Design Engine
SentinusAI® is our AI platform for de novo protein design and antibody engineering platform. Using deep learning to predict and optimize protein structures, it enables development of next-generation biologics.
| Task | Campaigns | Success | Success Rate | Condition |
|---|---|---|---|---|
| Affinity Maturation | 58 | 53 | 91.4% | Parent binder available |
| De Novo Design | 17 | 9 | 53% | No structure, no prior binder |
| Task | Round 1 (zero-shot) | Round 2 (RL iteration) | Lift |
|---|---|---|---|
| Affinity Maturation | 21.5% | 43.8% | +22.3 pp |
| De Novo Design | 7.5% | 30% | +22.5 pp |
| Target / Program | Format | KD |
|---|---|---|
| IL-15 × IL-21 | Bispecific | ~0.09 pM |
| Anti-C1q | mAb | 1–20 pM |
| TNFα – OX40L | Bispecific | 8.6 pM |
| TL1A × p40 | Bispecific | 23 pM |
| Anti-VEGF | scFv-IgG | 27.8–34.6 pM |
| Anti-IL-36R | Fab | < 1 pM* |
| Anti-TROP2 | ADC | 0.37–0.43 nM |
| Anti-B7-H3 | ADC-enabling | ~0.56 nM |
| Metric | Count | Detail |
|---|---|---|
| Internal pipeline | 37 | Total programs |
| With positive preclinical data | 28 | Available for licensing / partnering |
| ADC-ready oncology targets | 7 | Validated by FACS + internalization |
| Therapeutic areas | 3 | Oncology · Immunology · Metabolic |
| Dimension | SentinusAI® | Traditional 3D Workflow |
|---|---|---|
| Compute cost | 1× | ~10,000× |
| Design round duration | 1–2 weeks | months |
| Concurrent programs | 100+ | a few |
| Wet-lab candidates per round | 20–50 | thousands |
| Structure requirement | None (sequence-only) | Co-crystal or predicted complex |
Antibody Variants Evaluated
Small Molecule Design Engine
CarbonAI® is our advanced AI platform for small molecule drug discovery. It leverages deep learning models trained on proprietary chemical data to generate novel compounds with optimized properties for target engagement, selectivity, and drug-like characteristics.
AI-powered retrosynthetic analysis and route optimization for any molecule.
Try SynMagic Demo →Synthesis Success Rate
Cell Programming AI Engine
CellulaAI® harnesses machine learning to optimize cell engineering. Using AI to program cellular behavior, it accelerates development of cell therapies including CAR-T, stem cell treatments, and gene-edited cellular products.
Faster Cell Line Development
Natural Molecules AI Engine
NatmolAI® unlocks the therapeutic potential of natural products. Our AI analyzes vast natural compound libraries to identify bioactive molecules and optimize their drug-like properties while maintaining efficacy.
Wet Lab to Validation
Advanced Peptide Design Engine
PeptideAI® designs next-generation peptide therapeutics with enhanced stability, selectivity, and bioavailability. Our AI platform enables rapid optimization of peptide sequences for diverse therapeutic applications.
Improved Stability
Synthetic Biology Engine
BioSynthAI® enables the design of engineered biological systems. From metabolic pathway optimization to synthetic gene circuits, our AI accelerates the development of bio-manufactured therapeutics and materials.
Development Cost Reduction
Chemical Formulation Design Engine
FormulaAI® predicts formulation solutions for enhanced bioavailability, stability, and delivery. Our AI optimizes excipient selection and process parameters to de-risk formulation development.
Faster to Formulation Fit
New Material Design Engine
MaterialAI® discovers novel materials for drug delivery and medical devices. Using AI to predict material properties, it accelerates development of biocompatible materials with targeted functionality.
Faster Material Discovery
Adaptive Cosmetic Innovation Engine
CosmeticAI® brings AI-driven innovation to the cosmetic industry. Our platform designs novel active ingredients and formulations that meet stringent safety and efficacy standards for skincare and personal care.
Faster Innovation Cycles
RNA Design Engine
SenseAI® designs optimized RNA therapeutics including mRNA, siRNA, and ASOs. Our AI predicts secondary structures, stability, and efficacy to accelerate RNA-based drug development.
Improved Expression
Partner with Ainnocence to leverage our AI platforms for your therapeutic programs.
Schedule a Consultation